title: Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
abstract: OBJECTIVE
  To analyze a single center's experiences with ocriplasmin on vitreomacular traction (VMT) and the rate of VMT release, full-thickness macular hole (full-thickness MH) closure, and best-corrected visual acuity (BCVA) changes.
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  Single-center study of 58 eyes of 56 patients who received intravitreal ocriplasmin for VMT with or without full-thickness MH. VMT release, full-thickness MH closure, visual acuity changes, and anatomic characteristics on spectral-domain optical coherence tomography (SD OCT) were analyzed.
  
  
  RESULTS
  VMT resolved in 29 of 58 eyes (50%) and nonsurgical closure of full-thickness MH was achieved in 4 of 15 eyes (27%). Mean logMAR BCVA among all treated eyes improved from 0.51 (20/65) at baseline to 0.36 (20/46) at final follow-up (P = .0018) with mean follow-up of 8.7 months. When compared to eyes without VMT release, eyes with successful vitreomacular release had a better pretreatment BCVA (20/48 vs 20/89, P = .004) and final follow-up BCVA (20/31 vs 20/68, P = .0001). Improvement in BCVA was significant in eyes with VMT release (P = .0001). Transient ellipsoid zone changes were noted in 26% of treated eyes (n = 15), of which 14 had successful VMT release. Transient subfoveal fluid accumulation was noted in all these patients with vitreomacular release. Mean time to resolution of ellipsoid zone changes was within 38 days.
  
  
  CONCLUSIONS
  In clinical practice, intravitreal injection of ocriplasmin achieved VMT release in approximately one half of treated eyes, with a 27% closure rate for full-thickness MH. Transient ellipsoid changes were evident in 26% of treated eyes, more common in eyes with successful VMT release.
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Priya
authors: P
authors: Sharma
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Alexander
authors: A
authors: Juhn
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Samuel K
authors: SK
authors: Houston
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Mitchell
authors: M
authors: Fineman
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Allen
authors: A
authors: Chiang
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Allen
authors: A
authors: Ho
authors: Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: cregillo@aol.com.
authors: Carl
authors: C
authors: Regillo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012167:Retinal Perforations / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D016326:Extracellular Matrix Proteins; D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin